Finally, the above radiolabelled derivatives have been tested in vivo in two preclinical cancer models (prostate and high grade glioma), to evaluate their pharmacokinetic properties, also by comparison with above mentioned well known and routinely used [18F]F-PSMA-1007. The gene discussed is FOLH1; the disease is central nervous system cancer.